Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children (SchistoSAM): protocol of a proof-of-concept, open-label, two-arm, individually-randomised controlled trial

Clémentine Roucher, Isabel Brosius, Moustapha Mbow, Babacar Thiendella Faye, Annelies De Hondt, Bart Smekens, Diana Arango, Christophe Burm, Achilleas Tsoumanis, Linda Paredis, Yven van Herrewege, Idzi Potters, Badara Cisse, Souleymane Mboup, Katja Polman, Emmanuel Bottieau, Clémentine Roucher, Isabel Brosius, Moustapha Mbow, Babacar Thiendella Faye, Annelies De Hondt, Bart Smekens, Diana Arango, Christophe Burm, Achilleas Tsoumanis, Linda Paredis, Yven van Herrewege, Idzi Potters, Badara Cisse, Souleymane Mboup, Katja Polman, Emmanuel Bottieau

Abstract

Introduction: Alternative drugs and diagnostics are needed for the treatment and control of schistosomiasis. The exclusive use of praziquantel (PZQ) in mass drug administration programmes may result in the emergence of drug resistance. PZQ has little activity against Schistosoma larvae, thus reinfection remains a problem in high-risk communities. Furthermore, the insufficient sensitivity of conventional microscopy hinders therapeutic response assessment. Evaluation of artesunate-mefloquine (AM) as a Novel Alternative Treatment for Schistosomiasis in African Children (SchistoSAM) aims to evaluate the safety and efficacy of the antimalarial combination artesunate-mefloquine, re-purposed for the treatment of schistosomiasis, and to assess the performance of highly sensitive novel antigen-based and DNA-based assays as tools for monitoring treatment response.

Methods and analysis: The SchistoSAM study is an open-label, two-arm, individually randomised controlled non-inferiority trial, with a follow-up of 48 weeks. Primary school-aged children from the Richard Toll district in northern Senegal, an area endemic for Schistosoma mansoni and Schistosoma haematobium, are allocated to the AM intervention arm (3-day courses at 6-week intervals) or the PZQ control arm (single dose of 40 mg/kg). The trial's primary endpoints are the efficacy (cure rate (CR), assessed by microscopy) and safety (frequency and pattern of drug-related adverse events) of one AM course versus PZQ at 4 weeks after treatment. Secondary endpoints include (1) cumulative CR, egg reduction rate and safety after each additional course of AM, and at weeks 24 and 48, (2) prevalence and severity of schistosomiasis-related morbidity and (3) malaria prevalence, incidence and morbidity, both after 24 and 48 weeks. CRs and intensity reduction rates are also assessed by antigen-based and DNA-based diagnostic assays, for which performance for treatment monitoring is evaluated.

Ethics and dissemination: Ethics approval was obtained both in Belgium and Senegal. Oral assent from the children and signed informed consent from their legal representatives was obtained, prior to enrolment. The results will be disseminated in peer-reviewed journals and at international conferences.

Trial registration number: NCT03893097; pre-results.

Keywords: adverse events; clinical trials; molecular diagnostics; parasitology; tropical medicine.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flowchart. AM, artesunate-mefloquine; PZQ, praziquantel; (S)AE, (serious) adverse event.

References

    1. Colley DG, Bustinduy AL, Secor WE, et al. . Human schistosomiasis. Lancet 2014;383:2253–64. 10.1016/S0140-6736(13)61949-2
    1. WHO . Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000-2016, 2018.
    1. GBD 2016 Causes of Death Collaborators . Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study 2016. Lancet 2017;390:1151–210. 10.1016/S0140-6736(17)32152-9
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet 2017;390:1211–59. 10.1016/S0140-6736(17)32154-2
    1. Murray CJL, Vos T, Lozano R, et al. . Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012;380:2197–223. 10.1016/S0140-6736(12)61689-4
    1. McManus DP, Dunne DW, Sacko M, et al. . Schistosomiasis. Nat Rev Dis Primers 2018;4:13. 10.1038/s41572-018-0013-8
    1. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005;365:1561–9. 10.1016/S0140-6736(05)66457-4
    1. Zwang J, Olliaro P. Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. Parasit Vectors 2017;10:47. 10.1186/s13071-016-1958-7
    1. Zwang J, Olliaro PL. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis 2014;8:e3286. 10.1371/journal.pntd.0003286
    1. WHO preventive chemotherapy in human helminthiasis 2006.
    1. Meurs L, Mbow M, Vereecken K, et al. . Epidemiology of mixed Schistosoma mansoni and Schistosoma haematobium infections in northern Senegal. Int J Parasitol 2012;42:305–11. 10.1016/j.ijpara.2012.02.002
    1. Webster BL, Diaw OT, Seye MM, et al. . Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns. Acta Trop 2013;128:292–302. 10.1016/j.actatropica.2012.09.010
    1. Bergquist R, Utzinger J, Keiser J. Controlling schistosomiasis with praziquantel: how much longer without a viable alternative? Infect Dis Poverty 2017;6:74. 10.1186/s40249-017-0286-2
    1. Cioli D, Pica-Mattoccia L, Basso A, et al. . Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol 2014;195:23–9. 10.1016/j.molbiopara.2014.06.002
    1. Wu W, Wang W, Huang Y-X. New insight into praziquantel against various developmental stages of schistosomes. Parasitol Res 2011;109:1501–7. 10.1007/s00436-011-2670-3
    1. Wang W, Wang L, Liang Y-S. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res 2012;111:1871–7. 10.1007/s00436-012-3151-z
    1. Pinto-Almeida A, Mendes T, de Oliveira RN, et al. . Morphological characteristics of Schistosoma mansoni PZQ-Resistant and -susceptible strains are different in presence of praziquantel. Front Microbiol 2016;7:594. 10.3389/fmicb.2016.00594
    1. Vale N, Gouveia MJ, Rinaldi G, et al. . Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother 2017;6110.1128/AAC.02582-16
    1. Geerts S, Gryseels B. Anthelmintic resistance in human helminths: a review. Trop Med Int Health 2001;6:915–21. 10.1046/j.1365-3156.2001.00774.x
    1. Melman SD, Steinauer ML, Cunningham C, et al. . Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 2009;3:e504. 10.1371/journal.pntd.0000504
    1. Siqueira LdaP, Fontes DAF, Aguilera CSB, et al. . Schistosomiasis: drugs used and treatment strategies. Acta Trop 2017;176:179–87. 10.1016/j.actatropica.2017.08.002
    1. Liu R, Dong H-F, Guo Y, et al. . Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasit Vectors 2011;4:201. 10.1186/1756-3305-4-201
    1. Xiao S-hua. Mefloquine, a new type of compound against schistosomes and other helminthes in experimental studies. Parasitol Res 2013;112:3723–40. 10.1007/s00436-013-3559-0
    1. Keiser J, Utzinger J. Antimalarials in the treatment of schistosomiasis. Curr Pharm Des 2012;18:3531–8. 10.2174/138161212801327293
    1. Pérez del Villar L, Burguillo FJ, López-Abán J, et al. . Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One 2012;7:e45867. 10.1371/journal.pone.0045867
    1. Elmorshedy H, Tanner M, Bergquist RN, et al. . Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: a randomized controlled trial. Acta Trop 2016;158:52–8. 10.1016/j.actatropica.2016.02.015
    1. Keiser J, Chollet J, Xiao S-H, et al. . Mefloquine-an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl Trop Dis 2009;3:e350. 10.1371/journal.pntd.0000350
    1. Abou-Shady OM, Mohammed SS, Attia SS, et al. . Therapeutic effect of mefloquine on Schistosoma mansoni in experimental infection in mice. J Parasit Dis 2016;40:259–67. 10.1007/s12639-014-0489-4
    1. Keiser J, N'Guessan NA, Adoubryn KD, et al. . Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis 2010;50:1205–13. 10.1086/651682
    1. Basra A, Mombo-Ngoma G, Melser MC, et al. . Efficacy of mefloquine intermittent preventive treatment in pregnancy against Schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trial. Clin Infect Dis 2013;56:e68–75. 10.1093/cid/cis976
    1. Cohee LM, Opondo C, Clarke SE, et al. . Preventive malaria treatment among school-aged children in sub-Saharan Africa: a systematic review and meta-analyses. Lancet Glob Health 2020;8:e1499–511. 10.1016/S2214-109X(20)30325-9
    1. Utzinger J, Becker SL, van Lieshout L, et al. . New diagnostic tools in schistosomiasis. Clin Microbiol Infect 2015;21:529–42. 10.1016/j.cmi.2015.03.014
    1. de Vlas SJ, Gryseels B. Underestimation of Schistosoma mansoni prevalences. Parasitol Today 1992;8:274–7. 10.1016/0169-4758(92)90144-Q
    1. Knopp S, Becker SL, Ingram KJ, et al. . Diagnosis and treatment of schistosomiasis in children in the era of intensified control. Expert Rev Anti Infect Ther 2013;11:1237–58. 10.1586/14787210.2013.844066
    1. Engels D, Sinzinkayo E, De Vlas SJ, et al. . Intraspecimen fecal egg count variation in Schistosoma mansoni infection. Am J Trop Med Hyg 1997;57:571–7. 10.4269/ajtmh.1997.57.571
    1. Verweij JJ, Stensvold CR. Molecular testing for clinical diagnosis and epidemiological investigations of intestinal parasitic infections. Clin Microbiol Rev 2014;27:371–418. 10.1128/CMR.00122-13
    1. Meurs L, Brienen E, Mbow M, et al. . Is PCR the next reference standard for the diagnosis of Schistosoma in stool? A comparison with microscopy in Senegal and Kenya. PLoS Negl Trop Dis 2015;9:e0003959. 10.1371/journal.pntd.0003959
    1. ten Hove RJ, Verweij JJ, Vereecken K, et al. . Multiplex real-time PCR for the detection and quantification of Schistosoma mansoni and S. haematobium infection in stool samples collected in northern Senegal. Trans R Soc Trop Med Hyg 2008;102:179–85. 10.1016/j.trstmh.2007.10.011
    1. Vinkeles Melchers NVS, van Dam GJ, Shaproski D, et al. . Diagnostic performance of Schistosoma real-time PCR in urine samples from Kenyan children infected with Schistosoma haematobium: day-to-day variation and follow-up after praziquantel treatment. PLoS Negl Trop Dis 2014;8:e2807. 10.1371/journal.pntd.0002807
    1. RMD technical brochure-rapid test for qualitative detection of: bilharzia (schistosomiasis).
    1. Greter H, Krauth SJ, Ngandolo BNR, et al. . Validation of a point-of-care circulating cathodic antigen urine cassette test for Schistosoma mansoni diagnosis in the Sahel, and potential cross-reaction in pregnancy. Am J Trop Med Hyg 2016;94:361–4. 10.4269/ajtmh.15-0577
    1. Armoo S, Cunningham LJ, Campbell SJ, et al. . Detecting Schistosoma mansoni infections among pre-school-aged children in southern Ghana: a diagnostic comparison of urine-CCA, real-time PCR and Kato-Katz assays. BMC Infect Dis 2020;20:301. 10.1186/s12879-020-05034-2
    1. Peralta JM, Cavalcanti MG. Is POC-CCA a truly reliable test for schistosomiasis diagnosis in low endemic areas? the trace results controversy. PLoS Negl Trop Dis 2018;12:e0006813. 10.1371/journal.pntd.0006813
    1. Adriko M, Standley CJ, Tinkitina B, et al. . Evaluation of circulating cathodic antigen (CCA) urine-cassette assay as a survey tool for Schistosoma mansoni in different transmission settings within Bugiri district, Uganda. Acta Trop 2014;136:50–7. 10.1016/j.actatropica.2014.04.001
    1. Lamberton PHL, Kabatereine NB, Oguttu DW, et al. . Sensitivity and specificity of multiple Kato-Katz thick smears and a circulating cathodic antigen test for Schistosoma mansoni diagnosis pre- and post-repeated-praziquantel treatment. PLoS Negl Trop Dis 2014;8:e3139. 10.1371/journal.pntd.0003139
    1. Colley DG, Andros TS, Campbell CH. Schistosomiasis is more prevalent than previously thought: what does it mean for public health goals, policies, strategies, guidelines and intervention programs? Infect Dis Poverty 2017;6:63. 10.1186/s40249-017-0275-5
    1. Colley DG, Binder S, Campbell C, et al. . A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of Schistosoma mansoni. Am J Trop Med Hyg 2013;88:426–32. 10.4269/ajtmh.12-0639
    1. Corstjens PLAM, van Lieshout L, Zuiderwijk M, et al. . Up-converting phosphor technology-based lateral flow assay for detection of Schistosoma circulating anodic antigen in serum. J Clin Microbiol 2008;46:171–6. 10.1128/JCM.00877-07
    1. Polman K, Diakhate MM, Engels D, et al. . Specificity of circulating antigen detection for schistosomiasis mansoni in Senegal and Burundi. Trop Med Int Health 2000;5:534–7. 10.1046/j.1365-3156.2000.00600.x
    1. van Dam GJ, Bogitsh BJ, van Zeyl RJ, et al. . Schistosoma mansoni: in vitro and in vivo excretion of CAA and CCA by developing schistosomula and adult worms. J Parasitol 1996;82:557–64.
    1. van Dam GJ, de Dood CJ, Lewis M, et al. . A robust dry reagent lateral flow assay for diagnosis of active schistosomiasis by detection of Schistosoma circulating anodic antigen. Exp Parasitol 2013;135:274–82. 10.1016/j.exppara.2013.06.017
    1. Knopp S, Corstjens PLAM, Koukounari A, et al. . Sensitivity and specificity of a urine circulating anodic antigen test for the diagnosis of Schistosoma haematobium in low endemic settings. PLoS Negl Trop Dis 2015;9:e0003752. 10.1371/journal.pntd.0003752
    1. Corstjens PLAM, Nyakundi RK, de Dood CJ, et al. . Improved sensitivity of the urine CAA lateral-flow assay for diagnosing active Schistosoma infections by using larger sample volumes. Parasit Vectors 2015;8:241. 10.1186/s13071-015-0857-7
    1. Hatz CF. The use of ultrasound in schistosomiasis. Adv Parasitol 2001;48:225–84. 10.1016/s0065-308x(01)48007-9
    1. Barda B, Coulibaly JT, Hatz C, et al. . Ultrasonographic evaluation of urinary tract morbidity in school-aged and preschool-aged children infected with Schistosoma haematobium and its evolution after praziquantel treatment: a randomized controlled trial. PLoS Negl Trop Dis 2017;11:e0005400. 10.1371/journal.pntd.0005400
    1. Webster JP, Koukounari A, Lamberton PHL, et al. . Evaluation and application of potential schistosome-associated morbidity markers within large-scale mass chemotherapy programmes. Parasitology 2009;136:1789–99. 10.1017/S0031182009006350
    1. Ochodo EA, Gopalakrishna G, Spek B, et al. . Circulating antigen tests and urine reagent strips for diagnosis of active schistosomiasis in endemic areas. Cochrane Database Syst Rev 2015:CD009579. 10.1002/14651858.CD009579.pub2
    1. Emukah E, Gutman J, Eguagie J, et al. . Urine heme dipsticks are useful in monitoring the impact of praziquantel treatment on Schistosoma haematobium in sentinel communities of delta state, Nigeria. Acta Trop 2012;122:126–31. 10.1016/j.actatropica.2012.01.002
    1. Bustinduy AL, Sousa-Figueiredo JC, Adriko M, et al. . Fecal occult blood and fecal calprotectin as point-of-care markers of intestinal morbidity in Ugandan children with Schistosoma mansoni infection. PLoS Negl Trop Dis 2013;7:e2542. 10.1371/journal.pntd.0002542
    1. Seck MC, Thwing J, Fall FB, et al. . Malaria prevalence, prevention and treatment seeking practices among nomadic pastoralists in northern Senegal. Malar J 2017;16:413. 10.1186/s12936-017-2055-x
    1. WHO . Basic laboratory methods in medical parasitology. Geneva: World Health Organization, 1991.
    1. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 1972;14:397–400.
    1. Casacuberta-Partal M, Hoekstra PT, Kornelis D, et al. . An innovative and user-friendly scoring system for standardised quantitative interpretation of the urine-based point-of-care strip test (POC-CCA) for the diagnosis of intestinal schistosomiasis: a proof-of-concept study. Acta Trop 2019;199:105150. 10.1016/j.actatropica.2019.105150
    1. Corstjens PLAM, De Dood CJ, Kornelis D, et al. . Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phosphor labels. Parasitology 2014;141:1841–55. 10.1017/S0031182014000626
    1. van Grootveld R, van Dam GJ, de Dood C, et al. . Improved diagnosis of active Schistosoma infection in travellers and migrants using the ultra-sensitive in-house lateral flow test for detection of circulating anodic antigen (CAA) in serum. Eur J Clin Microbiol Infect Dis 2018;37:1709–16. 10.1007/s10096-018-3303-x
    1. Pillay P, Taylor M, Zulu SG, et al. . Real-Time polymerase chain reaction for detection of Schistosoma DNA in small-volume urine samples reflects focal distribution of urogenital schistosomiasis in primary school girls in KwaZulu natal, South Africa. Am J Trop Med Hyg 2014;90:546–52. 10.4269/ajtmh.13-0406
    1. Obeng BB, Aryeetey YA, de Dood CJ, et al. . Application of a circulating-cathodic-antigen (CCA) strip test and real-time PCR, in comparison with microscopy, for the detection of Schistosoma haematobium in urine samples from Ghana. Ann Trop Med Parasitol 2008;102:625–33. 10.1179/136485908X337490
    1. Richter J, Campange G, Hatz G. Ultrasound in schistosomiasis. A practical guide to the standardized use of ultrasonography for the assessment of Schistosomiasis-related morbidity. World Health Organization, 2016.
    1. WHO haemoglobin concentrations for the diagnosis of anaemia and assessment of severity 2011.
    1. Hofmann N, Mwingira F, Shekalaghe S, et al. . Ultra-sensitive detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS Med 2015;12:e1001788. 10.1371/journal.pmed.1001788
    1. Oyebola KM, Aina OO, Idowu ET, et al. . A barcode of multilocus nuclear DNA identifies genetic relatedness in pre- and post-Artemether/Lumefantrine treated Plasmodium falciparum in Nigeria. BMC Infect Dis 2018;18:392. 10.1186/s12879-018-3314-3
    1. Witkowski B, Duru V, Khim N, et al. . A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis 2017;17:174–83. 10.1016/S1473-3099(16)30415-7
    1. Ariey F, Witkowski B, Amaratunga C, et al. . A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014;505:50–5. 10.1038/nature12876
    1. Vachot-Ganée L, Khim N, Iannello A, et al. . A novel field-based molecular assay to detect validated artemisinin-resistant K13 mutants. Malar J 2018;17:175. 10.1186/s12936-018-2329-y
    1. Agency EM ICH topic E 9 statistical principles for clinical trials step 5. note for guidance on statistical principles for clinical trials (CPMP/ICH/363/96) 1998.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe